Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75ￂ years and over with or without cirrhosis

Aim The aim of this study was to evaluate the efficacy and safety of 24-week daclatasvir (NS5A inhibitor) plus asunaprevir (NS3/4 A protease inhibitor) treatment for elderly patients with hepatitis C virus (HCV) genotype 1b infection. Methods This prospective, multicenter study consisted of 321 Japa...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology research 2017-03, Vol.47 (3), p.E120
Main Authors: Ogawa, Eiichi, Furusyo, Norihiro, Yamashita, Naoki, Kawano, Akira, Takahashi, Kazuhiro, Dohmen, Kazufumi, Nakamuta, Makoto, Satoh, Takeaki, Nomura, Hideyuki, Azuma, Koichi, Koyanagi, Toshimasa, Kotoh, Kazuhiro, Shimoda, Shinji, Kajiwara, Eiji, Hayashi, Jun
Format: Article
Language:English
Subjects:
Age
Alanine
Alanine transaminase
Cirrhosis
Fibrosis
Genotype & phenotype
Geriatrics
Hepatitis
Hepatitis C
Interferon
Liver
Liver cirrhosis
Side effects
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim The aim of this study was to evaluate the efficacy and safety of 24-week daclatasvir (NS5A inhibitor) plus asunaprevir (NS3/4 A protease inhibitor) treatment for elderly patients with hepatitis C virus (HCV) genotype 1b infection. Methods This prospective, multicenter study consisted of 321 Japanese HCV genotype 1b patients who were interferon-ineligible/intolerant or non-responders to interferon-based regimens, including 103 (32.1%) aged ≥75 years and 127 (39.6%) with cirrhosis. Sustained virological response (SVR) at 24 weeks after the end of treatment and adverse effects were analyzed according to age. Results The overall SVR rate was 90.3%. In terms of by age, 94.5% (69/73), 88.3% (128/145), and 90.3% (93/103) of the patients aged
ISSN:1386-6346
1872-034X
DOI:10.1111/hepr.12738